31 August 2023
BRAEMAR PLC
(the "Company")
Total Voting Rights
In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1, the total number of ordinary shares of 10 pence each in the capital of the Company in issue as at 31 August 2023 is 32,924,877, with each share carrying the right to one vote. The Company does not hold any shares in Treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.
For further information, contact:
| Braemar Plc | | | |
| James Gundy, Group Chief Executive Officer | Tel +44 (0) 20 3142 4100 | ||
| Grant Foley, Group Chief Financial Officer | | ||
| Rebecca-Joy Wekwete, Company Secretary | | ||
| Investec Bank plc | | ||
| Gary Clarence / Harry Hargreaves / Alice King | Tel +44 (0) 20 7597 5970 | ||
| Cenkos Securities plc
Ben Jeynes / Max Gould (Corporate Finance) Alex Pollen / Leif Powis (Sales) |
Tel +44 (0) 20 7397 8900
| ||
| Buchanan | | ||
| Charles Ryland / Jamie Hooper / Jack Devoy | Tel +44 (0) 20 7466 5000 | ||
Notes to Editors:
About Braemar Plc
Braemar provides expert advice in shipping investment, chartering, and risk management to enable its clients to secure sustainable returns and mitigate risk in the volatile world of shipping. Our experienced brokers work in tandem with specialist professionals to form teams tailored to our customers' needs, and provide an integrated service supported by a collaborative culture.
Braemar joined the Official List of the London Stock Exchange in November 1997 and trades under the symbol BMS. For more information, including our investor presentation, please visit www.braemar.com and follow Braemar on LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
